Oral compositions of MK2 pathway inhibitor for treatment of immune conditions
US11844801B2 · kind B2 · utility
1Cited by
8References
64Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 26, 2021 |
| Grant date | Dec 19, 2023 |
| Priority date | — |
| Expiry date | Jan 14, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to oral compositions of Compound I or a derivative thereof. Methods of use for treating an inflammatory condition are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.